News
Bacille Calmette-Guérin (BCG) revaccination is not efficacious for preventing sustained Mycobacterium tuberculosis infection, ...
Hosted on MSN1mon
Reasons to Retain QIAGEN Stock in Your Portfolio for NowThe QuantiFERON test delivered its sixth consecutive quarter of sales above $100 million, supported by solid demand in all regions from conversion gains against the tuberculin skin test.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results